ArticleClinical medicine (London, England)2016
Atopic eczema.
Article in Clinical medicine (London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Are behavioral interventions a better choice for atopic dermatitis patients? A meta-analysis of 6 randomized controlled trials.Anais brasileiros de dermatologiaPooled it
- Sex-specific developmental trajectories of eczema from infancy to age 26 years: A birth cohort study.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2022Article
- Vehicles for Drug Delivery and Cosmetic Moisturizers: Review and Comparison.Pharmaceutics · 2021Review
- Definition of Clinically Meaningful Within-Patient Changes in POEM and CDLQI in Children 6 to 11 Years of Age with Severe Atopic Dermatitis.Dermatology and therapy · 2021Article
- Advances in atopic dermatitis.Clinical medicine (London, England) · 2021Article
- Targeted Screening of Lactic Acid Bacteria With Antibacterial Activity TowardFrontiers in microbiology · 2021Article
- Effects of gut microbiome and environment on the development of eczema in Chinese infants.Medicine · 2020Article
- Severe adult-onset atopic dermatitis mistaken for cutaneous T-cell lymphoma in a medically complex patient.BMJ case reports · 2020Article
- Measurements of AMPs in stratum corneum of atopic dermatitis and healthy skin-tape stripping technique.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Atopic eczema is an itchy inflammatory skin disease with a chronic relapsing-remitting course; it has increased in prevalence in recent decades and now affects up to 25% of school-aged children in the developed world and up to 10% of adults. Recent advances in understanding the aetiology of eczema have focused interest on skin barrier dysfunction as a common precursor and pathological feature. In addition, genetically determined skin barrier dysfunction (associated with mutations in the gene encoding filaggrin) is known to predispose to multiple systemic atopic diseases. First-line treatments for atopic eczema focus on maintaining and repairing the skin barrier (emollients) and reducing inflammation (topical steroids); allergen and irritant avoidance are also important to achieve disease control. Second and third-line treatments include topical calcineurin inhibitors, ultraviolet light and systemic immunosuppressant therapies of which only ciclosporin is licenced for the treatment of atopic eczema in adults. Novel biological therapies are in phase II-III clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.